Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACHV 
Achieve Life Sciences Inc (ACHV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: ACHV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.61% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 244.28M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 8 | Beta 1.58 | 52 Weeks Range 1.84 - 5.78 | Updated Date 10/29/2025 |
52 Weeks Range 1.84 - 5.78 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.244 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.63% | Return on Equity (TTM) -120.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 117587847 | Price to Sales(TTM) - |
Enterprise Value 117587847 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 51104968 | Shares Floating 41529430 |
Shares Outstanding 51104968 | Shares Floating 41529430 | ||
Percent Insiders 4.47 | Percent Institutions 61.61 |
Upturn AI SWOT
Achieve Life Sciences Inc
Company Overview
History and Background
Achieve Life Sciences Inc. is a pharmaceutical company committed to the development and commercialization of cytisine for smoking cessation. It was formerly known as IG Bio, Inc. and changed its name in 2012. The company is focused on the development and potential regulatory approval of cytisine as a treatment for nicotine addiction.
Core Business Areas
- Pharmaceutical Development: Focuses on the clinical development and potential commercialization of cytisine for smoking cessation.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is typical of a development-stage pharmaceutical company, with departments focused on clinical research, regulatory affairs, and commercial planning.
Top Products and Market Share
Key Offerings
- Cytisine (varenicline alternative): Cytisine is a plant-based compound with a history of use in Central and Eastern Europe for smoking cessation. Achieve Life Sciences is developing cytisine as a potential alternative to varenicline (Chantix). Market share is currently 0% as it awaits FDA approval. Competitors are Pfizer(Chantix) and Johnson & Johnson (Nicorette).
Market Dynamics
Industry Overview
The smoking cessation market is large and growing, driven by increasing awareness of the health risks of smoking and a desire for effective treatment options.
Positioning
Achieve Life Sciences is positioned as a potential disruptor in the smoking cessation market with its cytisine candidate, offering a novel mechanism of action and a potentially favorable safety profile compared to existing treatments.
Total Addressable Market (TAM)
The global smoking cessation market is expected to reach USD 27.46 billion by 2029. Achieve Life Sciences is positioned to capture a portion of this TAM with the potential approval of cytisine.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for smoking cessation.
- Potentially favorable safety profile compared to existing treatments.
- Experienced management team.
- Well-defined clinical development plan.
Weaknesses
- Reliance on a single product candidate.
- Limited financial resources.
- Dependence on regulatory approval for commercialization.
- Lack of established commercial infrastructure.
Opportunities
- Successful completion of clinical trials and FDA approval.
- Partnerships with pharmaceutical companies for commercialization.
- Expansion into new markets.
- Development of new formulations of cytisine.
Threats
- Failure to obtain regulatory approval.
- Competition from existing smoking cessation treatments.
- Changes in regulatory landscape.
- Unfavorable clinical trial results.
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- NVS
Competitive Landscape
Achieve Life Sciences faces significant competition from established pharmaceutical companies with existing smoking cessation treatments. Its success depends on demonstrating the superiority of cytisine in terms of efficacy, safety, or cost.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, as Achieve Life Sciences is primarily focused on clinical development.
Future Projections: Future growth is dependent on the successful completion of clinical trials and FDA approval of cytisine. Analyst estimates vary depending on the likelihood of regulatory approval and commercial success.
Recent Initiatives: Recent initiatives include ongoing clinical trials of cytisine, efforts to secure funding, and preparations for potential commercialization.
Summary
Achieve Life Sciences is a high-risk, high-reward company focused on developing cytisine for smoking cessation. While the company has a promising product candidate, it faces significant regulatory and competitive hurdles. Its success hinges on positive clinical trial results and securing FDA approval, requiring robust financial backing and strategic partnerships to navigate the competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Achieve Life Sciences Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1995-10-13 | CEO & Executive Director Dr. Richard A. B. Stewart | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | |
Full time employees 25 | |||
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.